245 related articles for article (PubMed ID: 12489845)
1. Antiangiogenic effect by SU5416 is partly attributable to inhibition of Flt-1 receptor signaling.
Itokawa T; Nokihara H; Nishioka Y; Sone S; Iwamoto Y; Yamada Y; Cherrington J; McMahon G; Shibuya M; Kuwano M; Ono M
Mol Cancer Ther; 2002 Mar; 1(5):295-302. PubMed ID: 12489845
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Haspel HC; Scicli GM; McMahon G; Scicli AG
Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
[TBL] [Abstract][Full Text] [Related]
3. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
Mendel DB; Schreck RE; West DC; Li G; Strawn LM; Tanciongco SS; Vasile S; Shawver LK; Cherrington JM
Clin Cancer Res; 2000 Dec; 6(12):4848-58. PubMed ID: 11156244
[TBL] [Abstract][Full Text] [Related]
4. Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor.
Sawano A; Takahashi T; Yamaguchi S; Aonuma M; Shibuya M
Cell Growth Differ; 1996 Feb; 7(2):213-21. PubMed ID: 8822205
[TBL] [Abstract][Full Text] [Related]
5. Involvement of Flt-1 tyrosine kinase (vascular endothelial growth factor receptor-1) in pathological angiogenesis.
Hiratsuka S; Maru Y; Okada A; Seiki M; Noda T; Shibuya M
Cancer Res; 2001 Feb; 61(3):1207-13. PubMed ID: 11221852
[TBL] [Abstract][Full Text] [Related]
6. Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1.
Landgren E; Schiller P; Cao Y; Claesson-Welsh L
Oncogene; 1998 Jan; 16(3):359-67. PubMed ID: 9467961
[TBL] [Abstract][Full Text] [Related]
7. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.
Fong TA; Shawver LK; Sun L; Tang C; App H; Powell TJ; Kim YH; Schreck R; Wang X; Risau W; Ullrich A; Hirth KP; McMahon G
Cancer Res; 1999 Jan; 59(1):99-106. PubMed ID: 9892193
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of choroidal neovascularization by blocking vascular endothelial growth factor receptor tyrosine kinase.
Kami J; Muranaka K; Yanagi Y; Obata R; Tamaki Y; Shibuya M
Jpn J Ophthalmol; 2008; 52(2):91-98. PubMed ID: 18626731
[TBL] [Abstract][Full Text] [Related]
9. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1.
Wang H; Keiser JA
Circ Res; 1998 Oct; 83(8):832-40. PubMed ID: 9776730
[TBL] [Abstract][Full Text] [Related]
11. Design of a variant of vascular endothelial growth factor-A (VEGF-A) antagonizing KDR/Flk-1 and Flt-1.
Leenders W; Lubsen N; van Altena M; Clauss M; Deckers M; Löwik C; Breier G; Ruiter D; de Waal R
Lab Invest; 2002 Apr; 82(4):473-81. PubMed ID: 11950904
[TBL] [Abstract][Full Text] [Related]
12. Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation.
Kwak HJ; Park MJ; Park CM; Moon SI; Yoo DH; Lee HC; Lee SH; Kim MS; Lee HW; Shin WS; Park IC; Rhee CH; Hong SI
Int J Cancer; 2006 Jun; 118(11):2711-20. PubMed ID: 16388516
[TBL] [Abstract][Full Text] [Related]
13. Suppression of experimental choroidal neovascularization utilizing KDR selective receptor tyrosine kinase inhibitor.
Takeda A; Hata Y; Shiose S; Sassa Y; Honda M; Fujisawa K; Sakamoto T; Ishibashi T
Graefes Arch Clin Exp Ophthalmol; 2003 Sep; 241(9):765-72. PubMed ID: 12937991
[TBL] [Abstract][Full Text] [Related]
14. The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation.
Roberts DM; Kearney JB; Johnson JH; Rosenberg MP; Kumar R; Bautch VL
Am J Pathol; 2004 May; 164(5):1531-5. PubMed ID: 15111299
[TBL] [Abstract][Full Text] [Related]
15. Endothelial PAS domain protein 1 gene promotes angiogenesis through the transactivation of both vascular endothelial growth factor and its receptor, Flt-1.
Takeda N; Maemura K; Imai Y; Harada T; Kawanami D; Nojiri T; Manabe I; Nagai R
Circ Res; 2004 Jul; 95(2):146-53. PubMed ID: 15192019
[TBL] [Abstract][Full Text] [Related]
16. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
Abdollahi A; Lipson KE; Han X; Krempien R; Trinh T; Weber KJ; Hahnfeldt P; Hlatky L; Debus J; Howlett AR; Huber PE
Cancer Res; 2003 Jul; 63(13):3755-63. PubMed ID: 12839971
[TBL] [Abstract][Full Text] [Related]
17. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells.
Kanno S; Oda N; Abe M; Terai Y; Ito M; Shitara K; Tabayashi K; Shibuya M; Sato Y
Oncogene; 2000 Apr; 19(17):2138-46. PubMed ID: 10815805
[TBL] [Abstract][Full Text] [Related]
18. Src kinase becomes preferentially associated with the VEGFR, KDR/Flk-1, following VEGF stimulation of vascular endothelial cells.
Chou MT; Wang J; Fujita DJ
BMC Biochem; 2002 Dec; 3():32. PubMed ID: 12509223
[TBL] [Abstract][Full Text] [Related]
19. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats.
Roman CD; Choy H; Nanney L; Riordan C; Parman K; Johnson D; Beauchamp RD
J Surg Res; 2002 Jun; 105(1):43-7. PubMed ID: 12069500
[TBL] [Abstract][Full Text] [Related]
20. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
Ning S; Laird D; Cherrington JM; Knox SJ
Radiat Res; 2002 Jan; 157(1):45-51. PubMed ID: 11754641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
